Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial

ISEAS, SOLEDAD; ROCA, ENRIQUE L.; OCONNOR, JUAN M.; ELETA, MARTIN; SANCHEZ-LUCEROS, ANALIA; DI LEO, DANIELA; TINELLI, MARCELO; FARA, MARIA L.; SPITZER, EDUARDO; DEMARCO, IGNACIO A.; RIPOLL, GISELLE V.; PIFANO, MARINA; GARONA, JUAN; ALONSO, DANIEL F.

INVESTIGATIONAL NEW DRUGS

SPRINGER

Año: 2020 vol. 38 p. 1580 - 1587

0167-6997

Purpose The vasopressin analog desmopressin (dDAVP) is known to increase plasma levels of hemostatic factors, and preclinical studies in colorectal cancer models have demonstrated that it hampers tumor vascularization and metastatic progression. We evaluated safety and preliminary efficacy of dDAVP in rectal cancer patients with bleeding, before receiving specific oncologic treatment with surgery, chemotherapy and/or radiotherapy. Methods Patients with rectal cancer having moderate or severe rectal bleeding were enrolled in an open-label, dose-finding trial. Intravenous infusions of dDAVP were administered during two consecutive days in doses from 0.25 to 2.0 µg/kg, using single or twice daily regimen. Bleeding was graded using a score based on the Chutkan scale and tumor perfusion was evaluated by dynamic contrast-enhanced magnetic resonance imaging. Results The trial accrued a total of 32 patients. Dose-limiting toxicity occurred in patients receiving 1 µg/kg or higher. The most prominent treatment-related severe adverse event was hyponatremia. Most patients receiving the maximum tolerated dose of 0.5 µg/kg showed at least a partial hemostatic response and 58% developed a complete response with absence of bleeding at day 4 and/or at the last follow-up at day 14. Tumor perfusion was decreased in two-thirds of patients after dDAVP treatment. Conclusions dDAVP appeared as a promising hemostatic agent in rectal cancer patients with bleeding. Randomized clinical trials to confirm its effectiveness are warranted. Clinical trial registrationwww.clinicaltrials.gov NCT01623206.